LUCENTIS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUCENTIS (LUCENTIS).
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the biological activity of vascular endothelial growth factor A (VEGF-A), thereby preventing VEGF-A from interacting with its receptors (VEGFR1 and VEGFR2) on endothelial cells, reducing neovascularization and vascular permeability.
| Metabolism | Ranibizumab is a monoclonal antibody fragment; it is metabolized via general protein catabolism and is not subject to hepatic cytochrome P450 metabolism. |
| Excretion | Primarily metabolized via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible due to high molecular weight (48 kDa). Fecal/biliary elimination not characterized. Systemic clearance ~0.81 mL/hr. |
| Half-life | Terminal elimination half-life from vitreous humor: approximately 9 days (range 7–11 days) in humans. From serum: ~0.5 days (due to rapid systemic clearance). Clinical context: supports monthly intravitreal dosing. |
| Protein binding | Negligible binding to plasma proteins (<0.1%) due to high molecular weight and hydrophilic nature. |
| Volume of Distribution | Vitreous humor volume ~4 mL; systemic Vd after intravitreal administration is very small (~3 L) due to limited extravascular distribution. Not reported in L/kg. |
| Bioavailability | Intravitreal: near 100% into vitreous humor. Systemic absorption after intravitreal injection is minimal (~0.1% of dose). Subconjunctival or topical: negligible. |
| Onset of Action | Intravitreal injection: maximal reduction in central retinal thickness observed within 7 days; visual acuity improvement noted as early as 7 days. |
| Duration of Action | Intravitreal: effective suppression of VEGF-A for approximately 4 weeks, supporting monthly administration. Neovascularization regrowth may occur after 4–6 weeks. |
| Action Class | Vascular endothelial growth factor (VEGF) inhibitor for AMD |
Intravitreal injection of 0.5 mg (0.05 mL) once every 4 weeks (monthly).
| Dosage form | Injectable |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no dosing recommendations available. |
| Geriatric use | No specific dose adjustment required; clinical studies included elderly patients without evidence of different response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUCENTIS (LUCENTIS).
| Breastfeeding | Unknown if ranibizumab is excreted in human milk. Systemic absorption after intravitreal injection is negligible (<0.1% of plasma concentration), making significant excretion unlikely. However, caution advised. M/P ratio not available. |
| Teratogenic Risk | Ranibizumab is a VEGF inhibitor. Animal studies (cynomolgus monkeys) with intravitreal administration at systemic exposures up to 100 times the human exposure showed no evidence of teratogenicity; however, VEGF inhibition may impair fetal angiogenesis. No adequate human studies in pregnancy. Based on mechanism, potential risk for fetal harm (second and third trimester) due to anti-angiogenic effects. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Lucentis is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of its excipients. Intravitreal injections have been associated with endophthalmitis, retinal detachments, and intraocular inflammation.
| Serious Effects |
["Ocular or periocular infections","Known hypersensitivity to ranibizumab or any component of the product","Active intraocular inflammation"]
| Precautions | ["Endophthalmitis and retinal detachments: Proper aseptic injection technique required; monitor patients for signs of infection.","Increased intraocular pressure (IOP): May occur post-injection; monitor IOP before and after administration.","Arterial thromboembolic events: There is a potential risk, particularly in patients with a history of stroke or transient ischemic attack.","Fatal events in DME patients: In clinical trials, an increased incidence of fatal events was observed in patients with DME compared to controls; the cause is unclear.","Hypersensitivity: Serious allergic reactions, including anaphylaxis, have been reported.","Use in pregnancy: Limited data; consider risk-benefit."] |
Loading safety data…
| Fetal Monitoring | If used during pregnancy, monitor fetal growth via ultrasound (risk of fetal growth restriction). Assess for maternal hypertension and proteinuria due to possible systemic VEGF inhibition. |
| Fertility Effects | No specific human data. In animal studies, no adverse effects on fertility were noted at systemic exposures up to 100 times the human exposure after intravitreal dosing. |